HUP0303942A2 - Új vakcinakészítmények - Google Patents

Új vakcinakészítmények

Info

Publication number
HUP0303942A2
HUP0303942A2 HU0303942A HUP0303942A HUP0303942A2 HU P0303942 A2 HUP0303942 A2 HU P0303942A2 HU 0303942 A HU0303942 A HU 0303942A HU P0303942 A HUP0303942 A HU P0303942A HU P0303942 A2 HUP0303942 A2 HU P0303942A2
Authority
HU
Hungary
Prior art keywords
antigen
vaccine composition
novel vaccine
hpv
hsv
Prior art date
Application number
HU0303942A
Other languages
English (en)
Inventor
Serge Debrus
Nathalie Louise Mathy
Gerald Voss
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of HUP0303942A2 publication Critical patent/HUP0303942A2/hu
Publication of HUP0303942A3 publication Critical patent/HUP0303942A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

A jelen találmány vakcinakészítményre vonatkozik, amely legalább egyhumán immundeficiencia vírus (HIV) antigént és az alábbi antigénekközül az egyiket vagy mindkettőt tartalmazza: i) legalább egy herpessimplex vírus (HSV) antigént és ii) legalább egy humán papillomavírus(HPV) antigént. A találmány tárgykörébe tartozik továbbá az újvakcinakészítmények előállítására szolgáló eljárás is. Ó
HU0303942A 2001-04-27 2002-04-25 Novel vaccine composition HUP0303942A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0110431A GB0110431D0 (en) 2001-04-27 2001-04-27 Novel compounds
PCT/EP2002/004966 WO2002087614A2 (en) 2001-04-27 2002-04-25 Multivalent vaccine comprising an hiv antigen and an hsv antigen and/or an hpv antigen

Publications (2)

Publication Number Publication Date
HUP0303942A2 true HUP0303942A2 (hu) 2004-03-01
HUP0303942A3 HUP0303942A3 (en) 2005-11-28

Family

ID=9913641

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0303942A HUP0303942A3 (en) 2001-04-27 2002-04-25 Novel vaccine composition

Country Status (20)

Country Link
US (1) US20040131638A1 (hu)
EP (1) EP1381390A2 (hu)
JP (1) JP2004531540A (hu)
KR (1) KR20040030599A (hu)
CN (1) CN1522153A (hu)
AR (1) AR034312A1 (hu)
AU (1) AU2002310802B2 (hu)
BR (1) BR0209161A (hu)
CA (1) CA2445310A1 (hu)
CZ (1) CZ20032942A3 (hu)
GB (1) GB0110431D0 (hu)
HU (1) HUP0303942A3 (hu)
IL (1) IL158428A0 (hu)
MX (1) MXPA03009698A (hu)
MY (1) MY134041A (hu)
NO (1) NO20034695L (hu)
NZ (1) NZ529039A (hu)
PL (1) PL367134A1 (hu)
WO (1) WO2002087614A2 (hu)
ZA (1) ZA200308188B (hu)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL201482B1 (pl) 1998-10-16 2009-04-30 Smithkline Beecham Biolog Sposoby wytwarzania kompozycji szczepionki oraz kompozycja szczepionki
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US9045727B2 (en) 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
GB0225786D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
GB0225788D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
GB0405480D0 (en) * 2004-03-11 2004-04-21 Istituto Superiore Di Sanito Novel tat complexes,and vaccines comprising them
GB0413510D0 (en) * 2004-06-16 2004-07-21 Glaxosmithkline Biolog Sa Vaccine
PE20060434A1 (es) * 2004-06-16 2006-06-08 Glaxosmithkline Biolog Sa Composicion inmunogenica que comprende plv o capsomeros de vph 16, vph 18 y al menos otro tipo de cancer de vph
US8778351B2 (en) * 2006-08-30 2014-07-15 University Of Rochester Combined human papillomavirus VLP/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors
JP5639361B2 (ja) 2006-09-08 2014-12-10 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｈｓｖ−１及びｈｓｖ−２ワクチン並びにその使用方法
US8865185B2 (en) 2006-09-08 2014-10-21 The Trustees Of The University Of Pennsylvania Methods of use for HSV-1 and HSV-2 vaccines
US10478490B2 (en) 2006-12-28 2019-11-19 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
WO2008085486A1 (en) * 2006-12-28 2008-07-17 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US8057804B2 (en) 2006-12-28 2011-11-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
ES2565846T3 (es) * 2008-05-26 2016-04-07 Cadila Healthcare Limited Vacuna combinada contra el sarampión-papiloma humano
WO2010074126A1 (ja) * 2008-12-25 2010-07-01 財団法人化学及血清療法研究所 組換え鶏伝染性コリーザワクチン及びその製造方法
EP2746394A4 (en) * 2011-08-19 2015-07-15 Ostrich Pharma Kk ANTIBODY AND COMPOSITION CONTAINING THE SAME
EP3209676A4 (en) * 2014-10-24 2018-03-28 Hpvvax, Llc Cancer and skin lesion treatment
BR112018067550A2 (pt) * 2016-02-27 2019-10-01 Hpvvax Llc métodos para tratar um paciente que tem câncer de pele, tumor benigno ou canceroso ou uma lesão associada a papilomavírus humano (hpv), e composição farmacêutica
PE20191547A1 (es) 2016-12-26 2019-10-24 Mogam Inst Biomedical Res Composicion de vacuna contra el herpes zoster

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9620795D0 (en) * 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
ATE454901T1 (de) * 1999-10-13 2010-01-15 Novartis Vaccines & Diagnostic Verfahren zur erhaltung zellimmuneantworten gegen proteinen

Also Published As

Publication number Publication date
GB0110431D0 (en) 2001-06-20
HUP0303942A3 (en) 2005-11-28
IL158428A0 (en) 2004-05-12
WO2002087614A3 (en) 2003-04-24
CN1522153A (zh) 2004-08-18
JP2004531540A (ja) 2004-10-14
CZ20032942A3 (cs) 2004-12-15
AU2002310802B2 (en) 2005-03-24
ZA200308188B (en) 2005-01-21
NZ529039A (en) 2005-02-25
NO20034695L (no) 2003-12-03
EP1381390A2 (en) 2004-01-21
KR20040030599A (ko) 2004-04-09
AR034312A1 (es) 2004-02-18
PL367134A1 (en) 2005-02-21
WO2002087614A2 (en) 2002-11-07
US20040131638A1 (en) 2004-07-08
MXPA03009698A (es) 2004-01-29
NO20034695D0 (no) 2003-10-20
MY134041A (en) 2007-11-30
BR0209161A (pt) 2004-08-03
CA2445310A1 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
HUP0303942A2 (hu) Új vakcinakészítmények
WO1999033868A3 (en) Human papillomavirus vaccine
HUP0301308A2 (hu) Emberi Papillomavírus-fertőzés gyógykezelése
BR9814606A (pt) Formulação de vacina e métodos de tratamento de um indivìduo infectado com um vìrus hpv e de prevenção de infecção por papiloma vìrus
BR9812139A (pt) Vacina
ECSP045300A (es) Antígenos virales
WO1994021807A3 (en) Defective mutant non-retroviral virus (e.g. hsv) as vaccine
MXPA02005639A (es) Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico.
HUP0303996A2 (hu) Vakcinakészítmények
HUP0102478A2 (hu) A HCV-burokfehérjék által alkotott részecskék alkalmazása vakcinázásban
HUP0202804A2 (hu) Új készítmény
HUP0202826A2 (hu) Új készítmény
EP1375652A3 (en) Oral compositions for HIV-Infected Subjects
FI940054A0 (fi) Peptider av humant papillomavirus foer anvaendning i kompositioner som inducerar human T-cellsvar
EA200701633A1 (ru) Вакцина на основе вирусоподобных частиц вируса папилломы человека 16 и вируса папилломы человека 18 l1
CA2097916A1 (en) Subunit papillomavirus vaccine and peptides for use therein
AU5848794A (en) Multiple-gene mutants of human immunodeficiency virus (hiv) for vaccine use
GB9417249D0 (en) A novel salt
WO2001060838A3 (en) Aids ancestral viruses and vaccines
HUP0001991A2 (hu) Varicella Zoster vírus 63-as géntermékkel szembeni vakcinák
ATE291089T1 (de) Verfahren zur herstellung von durch hefe exprimierte hpv typs 6 und 16 kapsid-proteinen
HUP0003511A2 (hu) Hepatitisz-B-vírus polipeptidek
IL139360A0 (en) Viral chimeras comprised of caev and hiv-1 genetic elements
DE60124725D1 (de) Herstellung eines chimeren papillomavirus
RU95104923A (ru) Штамм вируса герпеса кур "42" - деп для изготовления вакцины против болезни марека

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees